- Home
- Technology Platforms
Alfa Chemistry is a company dedicated to the development of innovative oligonucleotide therapeutics, pushing the boundaries of biomedical technologies and addressing unmet clinical needs around the world. With experienced experts and cutting-edge technology, we have established several technology platforms for oligonucleotide therapeutics, which vertically integrate the complete set of technologies to support the full life cycle of oligonucleotide therapeutics, from early R&D to commercialization. Our technology platforms mainly include sequence design, oligonucleotide synthesis, chemical modification, purification and analysis, delivery systems, and nonclinical evaluation. If you are interested in our technology platform or related services, please click the link below for more details.
Sequence design plays a crucial role in enhancing the stability of oligonucleotide therapeutics and the specific binding affinity between these therapeutics and their targets.
At Alfa Chemistry, advanced synthesis technologies make the efficient synthesis of oligonucleotides possible.
Chemical modifications, such as backbone, furanose sugar, and nucleobase modification, or their innovative combinations, can significantly enhance the specificity and reduce the off-target effects of oligonucleotide therapeutics.
With a proven technology platform for oligonucleotide purification and analysis, we are better able to support our customers.
Liver targeting delivery systems can support the rapid development of drug candidates to clinical stages. Our goal is to explore new delivery systems for extrahepatic tissue and cell-specific delivery of oligonucleotide therapeutics.
Nonclinical evaluation, including the pharmacokinetic study, pharmacodynamic study, and safety evaluation, is conducted to evaluate potential adverse effects of the oligonucleotides therapeutic candidates.